There are 2867 resources available
Considering the Options: Survivorship in Metastatic NSCLC and Potential Approaches for I-O–Experienced Patients
Presenter: Virginie Westeel
Session: Bristol Myers Squibb - The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers
Resources:
Webcast
How can patients’ involvement in clinical trial design save lives?
Presenter: Gilliosa Spurrier-Bernard
Session: Patient involvement in clinical research: Placing the patient at the centre
Resources:
Slides
Webcast
Articles of individualised treatment: How can we begin to individualise treatment using biomarkers and available therapies
Presenter: Gilles Freyer
Session: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer
Resources:
Webcast
New and emerging therapies for EGFR-mutant NSCLC
Presenter: Anne-Marie Dingemans
Session: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients
Resources:
Webcast
Optimally integrating tumour tissue NGS in the care pathway: Preanalytics, analytics, cost and reimbursement
Presenter: Javier Hernandez-Losa
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
Making Progress for Patients: How I-O Has Changed Outcomes in Unresectable MPM
Presenter: Dean Fennell
Session: Bristol Myers Squibb - The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers
Resources:
Webcast
Case study: Patients being involved in clinical research
Presenter: Estelle Lacointe Artzner
Session: Patient involvement in clinical research: Placing the patient at the centre
Resources:
Slides
Webcast
Discussion: What does the future hold for the management of EGFR-mutant NSCLC?
Presenter: Paul Hofman
Session: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients
Resources:
Webcast
The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems
Presenter: Oliver Gautschi
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
Live Q&A and Closing Remarks
Presenter: Dean Fennell
Session: Bristol Myers Squibb - The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers
Resources:
Webcast